Partnering to Fight TB: The Role of a TB Vaccine PDP
An Exhibitor's Workshop at the 2011 AAAS Annual Meeting
DATE: SUNDAY, FEBRUARY 20, 1:00-2:00 PM
VENUE: 2011 AAAS ANNUAL MEETING, WASHINGTON CONVENTION CENTER, ROOM 158AB
Speakers at the workshop will provide an overview of the state of the global TB epidemic and efforts to develop TB vaccines; the role of non-profit product development partnerships such as Aeras; and ways that scientists and researchers can add their voices to a global call for action on TB.
- Lewellys F. Barker, MD, Senior Medical Advisor, Aeras
- David Bryden, Senior Program Policy Officer at the Infectious Diseases Society of America's Center for Global Health Policy
- Claire Wingfield, TB/HIV Project Coordinator at the Treatment Action Group
TB is one of the world's deadliest infectious diseases, killing nearly 2 million men, women and children every year. Despite global efforts to prevent and treat TB, the epidemic is becoming more complex and difficult to diagnose and treat due in large part to the emergence of drug-resistant forms of TB and the emergence of the HIV epidemic. TB is responsible for the majority of AIDS deaths in Africa. The currently available vaccine, BCG, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. New TB vaccines are urgently needed as part of a comprehensive effort to stop TB.